10 hours Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus Zacks
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.